Natural selection of tumor variants in the generation of “tumor escape” phenotypes

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Inhibition of death receptor signals by cellular FLIP

Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,548

A cell culture model for T lymphocyte clonal anergy

Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M., & Takahashi, T. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820102.x · Cited by 1,505

Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice

Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465

CD4+CD25+ Immunoregulatory T Cells

McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395

Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

Hahne, M., Rimoldi, D., Schröter, M., Romero, P. J., Schreier, M. H., French, L. E., Schneider, P., Bornand, T., Fontana, A., Liénard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,236

The Role of MMP7 and Its Cross-Talk with the FAS/FASL System during the Acquisition of Chemoresistance to Oxaliplatin

Almendro, V., Ametller, E., García‐Recio, S., Collazo, O., Casas, I., Auge, J. M., Maurel, J., & Gascón, P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004728 · Cited by 86

A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

Hazama, S., Nakamura, Y., Tanaka, H., Hirakawa, K., TAHARA, K., Shimizu, R., Ozasa, H., Etoh, R., Sugiura, F., Okuno, K., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-108 · Cited by 87

Challenges and prospects of immunotherapy as cancer treatment

Rescigno, M., Avogadri, F., & Curigliano, G. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.07.003 · Cited by 84

Quiescent phenotype of tumor-specific CD8+ T cells following immunization

Monsurrò, V., Wang, E., Yamano, Y., Migueles, S. A., Panelli, M. C., Smith, K., Nagorsen, D., Connors, M., Jacobson, S., & Marincola, F. M. (2004) · Blood · doi:10.1182/blood-2004-02-0525 · Cited by 84

IL‐2‐activated haploidentical NK cells restore NKG2D‐mediated NK‐cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA

Kloeß, S., Huenecke, S., Piechulek, D., Esser, R., Koch, J., Brehm, C., Soerensen, J., Gardlowski, T., Brinkmann, A., Bader, P., et al. (2010) · European Journal of Immunology · doi:10.1002/eji.201040568 · Cited by 83

HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination

Cabrera, T., Lara, E., Romero, J. M., Maleno, I., Real, L. M., Ruiz‐Cabello, F., Valero, P. M., Camacho, F. M., & Garrido, F. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0226-7 · Cited by 83

Glioblastoma multiforme targeted therapy: The Chlorotoxin story

Cohen‐Inbar, O., & Zaaroor, M. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2016.04.012 · Cited by 80

TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors

Doorduijn, E. M., Sluijter, M., Querido, B. J., Oliveira, C. C., Achour, A., OSSENDORP, F. A., van der Burg, S. H., & van Hall, T. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83671 · Cited by 82

The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture

Garrido, F., Perea, F., Bernal, M., Sánchez‐Palencia, A., Aptsiauri, N., & Ruiz‐Cabello, F. (2017) · Vaccines · doi:10.3390/vaccines5010007 · Cited by 85

Genetically engineered Newcastle disease virus for malignant melanoma therapy

Zamarin, D., Vigil, A., Kelly, K. J., García‐Sastre, A., & Fong, Y. (2009) · Gene Therapy · doi:10.1038/gt.2009.14 · Cited by 81

Safety and Tolerability of Adoptive Cell Therapy in Cancer

Wolf, B., Zimmermann, S., Arber, C., Irving, M. B., Trueb, L., & Coukos, G. (2019) · Drug Safety · doi:10.1007/s40264-018-0779-3 · Cited by 79

Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy

Isser, A., Livingston, N. K., & Schneck, J. P. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120584 · Cited by 77

The Give-and-Take Interaction Between the Tumor Microenvironment and Immune Cells Regulating Tumor Progression and Repression

Pernot, S., Évrard, S., & Khatib, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850856 · Cited by 84

Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance

Zheng, N., Fang, J., Xue, G., Wang, Z., Li, X., Zhou, M., Jin, G., Rahman, M. M., McFadden, G., & Lu, Y. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.001 · Cited by 84

Complex humoral immune response against a benign tumor: Frequent antibody response against specific antigens as diagnostic targets

Comtesse, N., Zippel, A., Walle, S., Monz, D., Backes, C., Fischer, U., Mayer, J. M., Ludwig, N., Hildebrandt, A., Keller, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500404102 · Cited by 79

Autocrine Secretion of Fas Ligand Shields Tumor Cells from Fas-Mediated Killing by Cytotoxic Lymphocytes

Hallermalm, K., Geer, A. D., Kiessling, R. W., Levitsky, V., & Levitskaya, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0508 · Cited by 79

Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma

Wang, C., Shi, X., Song, H., Zhang, C., Wang, X., Huang, P., Dong, A., Zhang, Y., Kong, D., & Wang, W. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120579 · Cited by 77

Immunodominance and Immunodomination: Critical Factors in Developing Effective CD8+ T‐Cell–Based Cancer Vaccines

Chen, W., & McCluskey, J. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95006-4 · Cited by 78

Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy

Liu, G., Akasaki, Y., Khong, H. T., Wheeler, C. J., Das, A., Black, K. L., & Yu, J. S. (2005) · Oncogene · doi:10.1038/sj.onc.1208519 · Cited by 78

Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature

Facciponte, J. G., Ugel, S., Sanctis, F. D., Li, C., Wang, L., Nair, G. P., Sehgal, S., Raj, A., Matthaiou, E. I., Coukos, G., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67382 · Cited by 78

Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity

Terry, S., Buart, S., Tan, T. Z., Gros, G., Noman, M. Z., Lorens, J. B., Mami‐Chouaib, F., Thiery, J. P., & Chouaı̈b, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1271858 · Cited by 82

Immunotherapy for melanoma

Komenaka, I. K., Hoerig, H., & Kaufman, H. L. (2004) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2003.12.001 · Cited by 77

NF-κB Functions in Tumor Initiation by Suppressing the Surveillance of Both Innate and Adaptive Immune Cells

Wang, J., Ratnam, N. M., Byrd, J. C., & Guttridge, D. C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.049 · Cited by 81

Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models

Humeau, J., Lévesque, S., Kroemer, G., & Pol, J. G. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8885-3_21 · Cited by 84

Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents

Sharifzadeh, Z., Rahbarizadeh, F., Shokrgozar, M. A., Ahmadvand, D., Mahboudi, F., Jamnani, F. R., & Moghimi, S. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.010 · Cited by 76

Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer

da Silva, G. B. R. F., Silva, T. G. A., Duarte, R. A., Neto, N. L., Carrara, H. H. A., Donadi, E. A., Gonçalves, M. A. G., Soares, E. G., & Soares, C. P. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/250435 · Cited by 76

Enhancement of T-cell–Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer

Dings, R. P. M., Vang, K. B., Castermans, K., Popescu, F. E., Zhang, Y., Egbrink, M. G. A. O., Mescher, M. F., Farrar, M. A., Griffioen, A. W., & Mayo, K. H. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2443 · Cited by 77

Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen

Neelapu, S. S., Baskar, S., Gause, B. L., Kobrin, C. B., Watson, T. M., Frye, A. R., Pennington, R., Harvey, L. K., Jaffe, E. S., Robb, R. J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1071 · Cited by 77

Immunotherapy-induced CD8+ T Cells Instigate Immune Suppression in the Tumor

McGray, A. R., Hallett, R. M., Bernard, D., Swift, S. L., Zhu, Z., Teoderascu, F., VanSeggelen, H., Hassell, J. A., Hurwitz, A. A., Wan, Y., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.255 · Cited by 75

Role of Type I and II Interferons in Colorectal Cancer and Melanoma

Franco, S. D., Turdo, A., Todaro, M., & Stassi, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00878 · Cited by 76

Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy

Luevano, M., Madrigal, J. A., & Saudemont, A. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.17 · Cited by 76

MHC/HLA Class I Loss in Cancer Cells

Garrido, F. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-17864-2_2 · Cited by 74

Vaccine and antibody-directed T cell tumour immunotherapy

Dermime, S., Gilham, D. E., Shaw, D. M., Davidson, E. J., Meziane, E. K., Armstrong, A. C., Hawkins, R. E., & Stern, P. L. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.03.002 · Cited by 74

Gastric cancer cells exploit CD4+ cell‐derived CCL5 for their growth and prevention of CD8+ cell‐involved tumor elimination

Sugasawa, H., Ichikura, T., Kinoshita, M., Ono, S., Majima, T., Tsujimoto, H., Chochi, K., Hiroi, S., Takayama, E., Saitoh, D., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23401 · Cited by 74

Changes in Circulating Immunosuppressive Cytokine Levels of Cancer Patients After High Intensity Focused Ultrasound Treatment

Zhou, Q., Zhu, X., Zhang, J., Xu, Z.-L., Lu, P., & Wu, F. (2007) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2007.07.013 · Cited by 74

Expression of sperm protein 17 (Sp17) in ovarian cancer

Straughn, J. M., Shaw, D. R., Guerrero, A., Bhoola, S. M., Racelis, A., Wang, Z., Chiriva‐Internati, M., Grizzle, W. E., Alvarez, R. D., Lim, S. H., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.11617 · Cited by 74

Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting.

Todorova, K. O., Ignatova, I., Tchakarov, S., Altankova, I., Zoubak, S., Kyurkchiev, S., & Mincheff, M. S. (2005) · PubMed · Cited by 74

Multilevel omic data integration in cancer cell lines: advanced annotation and emergent properties

Liu, Y., Devescovi, V., Chen, S., & Nardini, C. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-14 · Cited by 72

Metabolic Imaging of Head and Neck Cancer Organoids

Shah, A. T., Heaster, T. M., & Skala, M. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170415 · Cited by 71

Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint

D’Assoro, A. B., Busby, R., Suino, K. M., Delva, E., Almodóvar-Mercado, G. J., Johnson, H. J., Folk, C., Farrugia, D. J., Vasile, V. C., Stivala, F., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207568 · Cited by 72

The ‘kiss of death’ by dendritic cells to cancer cells

Chan, C. W., & Housseau, F. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402235 · Cited by 75

Expression of interleukin-10 in patients with adenomyosis

Wang, F., Li, H., Yang, Z., Du, X., Cui, M., & Wen, Z. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.02.164 · Cited by 71

Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?

O’Malley, G., Heijltjes, M. T., Houston, A. M., Rani, S., Ritter, T., Egan, L. J., & Ryan, A. E. (2016) · Oncotarget · doi:10.18632/oncotarget.11354 · Cited by 72

Modulation of antigen‐presenting cells by HDAC inhibitors: implications in autoimmunity and cancer

Woan, K. V., Sahakian, E., Sotomayor, E. M., Seto, E., & Villagra, A. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2011.96 · Cited by 71

NKG2D CAR T‐cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors

Spear, P., Barber, A., Rynda‐Apple, A., & Sentman, C. L. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.17 · Cited by 72

Alcohol in Hepatocellular Cancer

Voigt, M. D. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.10.003 · Cited by 70

The tumour microenvironment: a novel target for cancer therapy

Hanna, E., Quick, J. S., & Libutti, S. K. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2008.01471.x · Cited by 73

Photodynamic Therapy Induced Cell Death Mechanisms in Breast Cancer

Mokoena, D. R., George, B. P. A., & Abrahamse, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910506 · Cited by 69

Why are systemic glioblastoma metastases rare? Systemic and cerebral growth of mouse glioblastoma

Mourad, P. D., Farrell, L., Stamps, L. D., Chicoine, M. R., & Silbergeld, D. L. (2005) · Surgical Neurology · doi:10.1016/j.surneu.2004.08.062 · Cited by 69

Tumor cell secretion of soluble factor(s) for specific immunosuppression

Kano, A. (2015) · Scientific Reports · doi:10.1038/srep08913 · Cited by 72

Baicalin from the extract of Scutellaria baicalensis affects the innate immunity and apoptosis in leukocytes of children with acute lymphocytic leukemia

Orzechowska, B., Chaber, R., Wiśniewska, A., Pajtasz‐Piasecka, E., Jatczak, B., Siemieniec, I., Gulanowski, B., Chybicka, A., & BŁACH-OLSZEWSKA, Z. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.10.005 · Cited by 68

Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches

Allen, C. T., Clavijo, P. E., Waes, C. V., & Chen, Z. (2015) · Cancers · doi:10.3390/cancers7040900 · Cited by 69

Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.

Park, J. H., & Brentjens, R. J. (2010) · PubMed · Cited by 66

Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells, Obesity and the Tumor Microenvironment of Breast Cancer

Ritter, A., Kreis, N., Hoock, S. C., Solbach, C., Louwen, F., & Yuan, J. (2022) · Cancers · doi:10.3390/cancers14163908 · Cited by 69

Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity

Avogadri, F., Merghoub, T., Maughan, M. F., Hirschhorn-Cymerman, D., Morris, J., Ritter, E., Olmsted, R. A., Houghton, A. N., & Wolchok, J. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012670 · Cited by 66

MAGE A3 Antigen-Specific Cancer Immunotherapeutic

Peled, N., Oton, A. B., Hirsch, F. R., & Bunn, P. A. (2008) · Immunotherapy · doi:10.2217/1750743x.1.1.19 · Cited by 66

Down-Regulation of HLA Class I Antigens in Prostate Cancer Tissues and Up-Regulation by Histone Deacetylase Inhibition

Kitamura, H., Torigoe, T., Asanuma, H., Honma, I., Sato, N., & Tsukamoto, T. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.03.109 · Cited by 66

Cancer Cells Regulate Lymphocyte Recruitment and Leukocyte-Endothelium Interactions in the Tumor-Draining Lymph Node

Carrière, V., Colisson, R., Jiguet‐Jiglaire, C., Bellard, E., Bouche, G., Saati, T. A., Amalric, F., Girard, J., & M’Rini, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1190 · Cited by 66

At the Intersection of Biomaterials and Gene Therapy: Progress in Non-viral Delivery of Nucleic Acids

Uludağ, H., Ubeda, A., & Ansari, A. S. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00131 · Cited by 67

Novel “Elements” of Immune Suppression within the Tumor Microenvironment

Gurusamy, D., Clever, D. C., Eil, R. L., & Restifo, N. P. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0117 · Cited by 64

HLA class I defects in malignant lesions: What have we learned?

Chang, C., Campoli, M. R., & Ferrone, S. (2003) · The Keio Journal of Medicine · doi:10.2302/kjm.52.220 · Cited by 65

Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases

Lengagne, R., Graff-Dubois, S., Garcette, M., Renia, L., Kato, M., Guillet, J.-G., Engelhard, V. H., Avril, M.-F., Abastado, J.-P., & Prévost-Blondel, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.130 · Cited by 64

Reemergence of neural crest stem cell-like states in melanoma during disease progression and treatment

Diener, J., & Sommer, L. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0351 · Cited by 64

Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer

Yasumoto, K., Hanagiri, T., & Takenoyama, M. (2009) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-008-0433-6 · Cited by 64

Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas

Walter, A., Barysch, M. J., Behnke, S., Dziunycz, P., Schmid, B., Ritter, E., Gnjatic, S., Kristiansen, G., Moch, H., Knuth, A. K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3136 · Cited by 64

Mechanisms of Tumor Evasion

Campoli, M. R., Ferrone, S., Zea, A. H., Rodrı́guez, P. C., & Ochoa, A. C. (2007) · Springer eBooks · doi:10.1007/0-387-27545-2_3 · Cited by 63

Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure

Abouzahr, S., Bismuth, G., Gaudin, C., Caroll, O., Endert, P. V., Jalil, A., Dausset, J. B., Vergnon, I., Richon, C., Kauffmann, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510454103 · Cited by 63

Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy

Turcotte, S., Gros, A., Tran, E., Lee, C. R., Wunderlich, J. R., Robbins, P. F., & Rosenberg, S. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1736 · Cited by 63

One cell, multiple roles: contribution of mesenchymal stem cells to tumor development in tumor microenvironment

Yang, X. F., Hou, J., Han, Z., Wang, Y., Hao, C., Wei, L., & Shi, Y. (2013) · Cell & Bioscience · doi:10.1186/2045-3701-3-5 · Cited by 63

Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu

Colombo, M., Mirandola, L., Chiriva‐Internati, M., Basile, A., Locati, M., Lesma, E. A., Chiaramonte, R., & Platonova, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01823 · Cited by 65

Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research

Overgaard, N. H., Fan, T. M., Schachtschneider, K. M., Principe, D. R., Schook, L. B., & Jungersen, G. (2018) · ILAR Journal · doi:10.1093/ilar/ily014 · Cited by 66

Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma

Rosenberg, S. A., Yang, J. C.-H., Robbins, P. F., Wunderlich, J. R., Hwu, P., Sherry, R. M., Schwartzentruber, D. J., Topalian, S. L., Restifo, N. P., Filie, A. C., et al. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200309000-00001 · Cited by 63

Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in patients with breast cancer: a meta-analysis

Zhou, Y., Shao, N., AiErken, N., Xie, C., Ye, R., Qian, X., Hu, Z., Zhang, J., & Lin, Y. (2017) · Journal of Cancer · doi:10.7150/jca.21030 · Cited by 64

Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers

Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 61

Nattokinase-Mediated Regulation of Tumor Physical Microenvironment to Enhance Chemotherapy, Radiotherapy, and CAR-T Therapy of Solid Tumor

Zhang, Y., Pei, P., Zhou, H., Xie, Y., Yang, S., Shen, W., Hu, L. T., Zhang, Y., Liu, T., & Yang, K. (2023) · ACS Nano · doi:10.1021/acsnano.2c12463 · Cited by 62

Prognostic value of tumor–stroma ratio combined with the immune status of tumors in invasive breast carcinoma

Vangangelt, K. M. H., van Pelt, G. W., Engels, C. C., Putter, H., Liefers, G., Smit, V. T. H. B. M., Tollenaar, R. A. �. �., Kuppen, P. J. K., & Mesker, W. E. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4617-6 · Cited by 62

Increased Immunogenicity of Tumor-Associated Antigen, Mucin 1, Engineered to Express α-Gal Epitopes: A Novel Approach to Immunotherapy in Pancreatic Cancer

Deguchi, T., Tanemura, M., Miyoshi, E., Nagano, H., Machida, T., Ohmura, Y., Kobayashi, S., Marubashi, S., Eguchi, H., Takeda, Y., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4313 · Cited by 61

Genomic Loss of Mismatched Human Leukocyte Antigen and Leukemia Immune Escape From Haploidentical Graft-Versus-Leukemia

Vago, L., Toffalori, C., Ciceri, F., & Fleischhauer, K. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.09.009 · Cited by 60

Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8+ T-cell Response and Protects Mice from Melanoma

Qiu, Z., Huang, H., Grenier, J. M., Perez, O. A., Smilowitz, H. M., Adler, B., & Khanna, K. M. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0044 · Cited by 59

Cellular Cancer Vaccines: an Update on the Development of Vaccines Generated from Cell Surface Antigens

Lokhov, P. G., & Balashova, E. E. (2010) · Journal of Cancer · doi:10.7150/jca.1.230 · Cited by 59

Computational pathology: Exploring the spatial dimension of tumor ecology

Nawaz, S., & Yuan, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.018 · Cited by 62

Modulating tumor physical microenvironment for fueling CAR-T cell therapy

Luo, Z. Y., Yao, X., Li, M., Fang, D., Fei, Y., Cheng, Z., Xu, Y., & Zhu, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114301 · Cited by 59

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy

Gutwillig, A., Santana-Magal, N., Farhat-Younis, L., Rasoulouniriana, D., Madi, A., Luxenburg, C., Cohen, J., Padmanabhan, K., Shomron, N., Shapira, G., et al. (2022) · eLife · doi:10.7554/elife.80315 · Cited by 59

T Cells and Stromal Fibroblasts in Human Tumor Microenvironments Represent Potential Therapeutic Targets

Barnas, J. L., Simpson-Abelson, M. R., Yokota, S. J., Kelleher, R. J., & Bankert, R. B. (2010) · Cancer Microenvironment · doi:10.1007/s12307-010-0044-5 · Cited by 58

Intralesional immunotherapy for melanoma

Hersey, P., & Gallagher, S. J. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23494 · Cited by 57

The “Emigration, Migration, and Immigration” of Prostate Cancer

Pienta, K. J., & Loberg, R. D. (2005) · Clinical Prostate Cancer · doi:10.3816/cgc.2005.n.008 · Cited by 56

CD1d-Restricted Natural Killer T Cells Can Down-regulate Tumor Immunosurveillance Independent of Interleukin-4 Receptor-Signal Transducer and Activator of Transcription 6 or Transforming Growth Factor-β

Terabe, M., Khanna, C., Bose, S., Melchionda, F., Mendoza, A., Mackall, C. L., Helman, L. J., & Berzofsky, J. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3421 · Cited by 57

Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects

Ding, Z., & Zhou, G. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/890178 · Cited by 58

Minimal residual disease in cancer therapy – Small things make all the difference

Blatter, S., & Rottenberg, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.003 · Cited by 55

T-Cell Tolerance in Cancer

Nurieva, R., Wang, J., & Sahoo, A. (2013) · Immunotherapy · doi:10.2217/imt.13.33 · Cited by 62

Potential role of immunotherapy in advanced non-small-cell lung cancer

de Mello, R. A., Veloso, A. F. D. H., Catarina, P. E. M., Nadine, S., & Αντωνίου, Γ. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s90459 · Cited by 56

Therapeutic applications of the cancer immunoediting hypothesis

Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59

Immunosuppressive niche engineering at the onset of human colorectal cancer

Gatenbee, C., Baker, A., Schenck, R. O., Strobl, M. A. R., West, J., Neves, M. P., Hasan, S. Y., Lakatos, E., Martinez, P., Cross, W. C. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29027-8 · Cited by 54

Val-BoroPro Accelerates T Cell Priming via Modulation of Dendritic Cell Trafficking Resulting in Complete Regression of Established Murine Tumors

Walsh, M. P., Duncan, B. B., Larabee, S. M., Krauss, A. C., Davis, J. P. E., Cui, Y., Kim, S. Y., Guimond, M., Bachovchin, W. W., & Fry, T. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058860 · Cited by 56

Development of effective immunotherapy for the treatment of patients with cancer

Rosenberg, S. A. (2004) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2004.01.025 · Cited by 55

The adaptive immune response to sporadic cancer

Willimsky, G., & Blankenstein, T. J. F. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00578.x · Cited by 61

Constitutive expression of TGF-bêta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma.

Toutirais, O., Chartier, P., Dubois, D., Bouet, F., Lévêque, J., Quémener, V., & Genetet, N. (2003) · PubMed · Cited by 55

A novel Salmonella Typhi-based immunotherapy promotes tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model of breast cancer

Alejandrina, V., Gravisaco, M. J., Pasetti, M. F., Croci, M., Colombo, L. L., Rodríguez, C., Mongini, C., & Waldner, C. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.11.017 · Cited by 54

Blockade of transforming growth factor-β signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle

Zhang, Q., Yang, X. J., KUNDU, S. D., Pins, M., Javonovic, B., Meyer, R., Kim, S., Greenberg, N. M., Kuzel, T. M., Meagher, R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0109 · Cited by 56

Long non-coding RNAs involved in metastasis of gastric cancer

Lin, M.-T., Song, H., & Ding, X. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i33.3724 · Cited by 52

Michor F: A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability

Iwami, S., Haeno, H., & Franziska Michor, A. (2016)

A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability

Iwami, S., Haeno, H., & Michor, F. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002370 · Cited by 14

Immunotherapy and immunoselection ? tumour escape as the final hurdle

Pawelec, G. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.02.091 · Cited by 30

Strategies for tumor immune escape

Piemonti, L., Zerbi, A., & Carlo, V. D. (2003) · Drugs of today · doi:10.1358/dot.2003.39.9.799478 · Cited by 8

Abstract 4034: Immunotherapy generates selective pressure to create an escape tumor with increased susceptibility to treatment with T cell based therapies

Pan, J. H., Vodnala, S. K., Eil, R. L., Yu, Z., Gartner, J. J., Clever, D. C., Roychoudhuri, R., Patel, S. J., Klebanoff, C. A., Sukumar, M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4034